US FDA mulling new strategies for OK'ing early-stage Alzheimer's meds
This article was originally published in Scrip
Recognizing that Alzheimer's drug development has increasingly been shifting to the earlier stages of the disease – before the onset of noticeable dementia – US regulators are taking steps to help industry meet the most difficult challenges of assessing functional impairment, suggesting this week it might be feasible for the agency to approve new medicines through the FDA's accelerated approval pathway on the basis of evaluating cognitive outcome alone.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.